Standard & High Dose Irinotecan Based on UGT1A1 Genotype for First-line

Status Recruiting

Clinical Trial Summary

In the current treatment of colon cancer, the definition of locally advanced colon cancer (LACC) is controversial, and the clinical trial evidence which support treatment for LACC is not clear. Irinotecan (CPT-11) combined with fluoropyrimidine (5FU, capecitabine) is main chemotherapy regimen for patients with advanced colorectal cancer. Whether this regimen also could be effectively applied for patients with locally advanced colon cancer? It is worthy of clinicians to conduct research. In recent studies, the literature indicated that the the uridine diphosphate glucuronide transfer enzyme (UGT1A1) is an important metabolic enzymes associated with drug metabolism of CPT-11. The gene polymorphism of UGT1A1 is related to delayed diarrhea and neutropenia caused by irinotecan. Irinotecan dose-exploration study found that the maximum tolerated dose for irinotecan in patients with UGT1A1*28 homozygous variant genotypes was significantly lower compared with the wild genotype. The studies based on Asian patients suggested that the gene variant of UGT1A1*6 also have similar impacts. At present, the studies of irinotecan dose adjustment based on the UGT1A1 gene polymorphisms has not yet come to the consistency of conclusions. The frequency of UGT1A1 gene polymorphisms between different races is significant different, irinotecan dose exploratory study based on Chinese patients has not been carried out.

This study focus on prospectively adverse reactions, optimal efficacy and R0 resection rate of the patients with LACC who treated by dose-adjusted irinotecan based on the genotypes of UGT1A1.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Colonic Neoplasms

Clinical Trial Details

NCT number	NCT01826396
Study type	Interventional
Source	Colorectal Cancer Institute of the Heilongjiang Academy of Medical Sciences
Contact	Zheng Jiang, doctor
Phone	+81 451 86297661
Email	dr.jiangzheng@gmail.com
Status	Recruiting
Phase	Phase 2
Start date	April 2013
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03746353` - Early Closure Versus Conventional Closure in Postoperative Patients With Low Anteriresection for Rectal Cancer	N/A
Recruiting	`NCT05809999` - IBD Neoplasia Surveillance RCT	N/A
Recruiting	`NCT06041945` - Artificial Intelligence to Implement Cost-saving Strategies for Colonoscopy Screening Based on in Vivo Prediction of Polyp Histology	N/A
Not yet recruiting	`NCT02688699` - Additive Hemostatic Efficacy of EndoClot After EMR or ESD in the Gastrointestinal Tract	Phase 4
Not yet recruiting	`NCT03175146` - A Study to See Whether Stereotactic Body RadioTherapy (SBRT) Can Shrink Tumours Within the Liver Safely	N/A
Completed	`NCT02529007` - Endo-cuff Assisted Vs. Standard Colonoscopy for Polyp Detection in Bowel Cancer Screening	N/A
Not yet recruiting	`NCT01929499` - Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer	Phase 2
Completed	`NCT01681472` - PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer	Phase 1/Phase 2
Completed	`NCT01438645` - ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy	N/A
Completed	`NCT00535652` - Concentration of Ertapenem in Colorectal Tissue	Phase 4
Terminated	`NCT00267787` - Molecular Genetic and Pathological Studies of Anal Tumors
Completed	`NCT05498051` - Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Submucosal Bevacizumab-800CW.	N/A
Recruiting	`NCT05068180` - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients	Phase 4
Recruiting	`NCT03314896` - Laparoscopic Surgery for T4 Tumor of the Colon Cancer (LST4C Trial)	N/A
Not yet recruiting	`NCT02777437` - Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer	Phase 2/Phase 3
Not yet recruiting	`NCT02852915` - Laparoscopic Surgery for T4 Tumor of the Colon Cancer	Phase 3
Completed	`NCT00997802` - Japanese National Computed Tomographic (CT) Colonography Trial	N/A
Completed	`NCT01056913` - NITI CAR27 (ColonRing) Compression Anastomosis in Colorectal Surgery	Phase 4
Completed	`NCT00537901` - First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study	N/A
Completed	`NCT00470782` - Aerobic Capacity and Body Composition in Colon Cancer Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Standard and High Dose Irinotecan Based on UGT1A1 Genotype for First-line Treatment of Locally Advanced Colon Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms